When novel drugs and biologics hit the market, the treatment horizon for many patients is suddenly broadened. US Food and Drug Administration (FDA) ‘firsts’ can present a vital step toward advancing the health of patients. Deborah Komlos at Clarivate explores how these ‘first’ therapeutic approvals bring patients hope during difficult times.
